# A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06417554/  
OnCo record `nct06417554` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-A2102, Adebrelimab and Disitamab vedotin in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06417554 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 80 participants planned, started 2024-05-27 and due to reach its primary completion in 2031-12-31. Interventions recorded: SHR-A2102, SHR-A2102 ; Adebrelimab injection and SHR-A2102 + Disitamab Vedotin For Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06417554
- Phase: 1/2
- Setting: A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06417554: https://clinicaltrials.gov/study/NCT06417554

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06417554.json